Search
ACADIA Pharmaceuticals Inc
ACADAdd to Watchlist
20.110USD
+0.160+0.80%
Close 10-05 16:00（ET）
3.44BMarket Cap
9.01P/E TTM
ACADIA Pharmaceuticals Inc (ACAD) Stock Price Target & Forecast
Analyst Rating
Based on 21 analysts giving stock ratings to ACADIA Pharmaceuticals Inc in the past month.
Buy
6 Strong Buy
10 Buy
4 Hold
1 Sell
0 Strong Sell
Target Price
32.056USD+60.68%
ACAD Analyst Recommendation Trends
In the current month, ACAD has received 10 Buy Ratings, 4 Hold Ratings, and 1 Sell Ratings. ACAD average Analyst price target in the last month is 32.056.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
6
5
5
5
5
5
5
4
10
10
11
11
11
11
11
11
4
4
4
4
4
4
4
5
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
21
20
21
21
21
21
21
21
ACAD Analyst Rating for Peer Comparison
Updated: Oct 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
18
0
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
IQVIA Holdings Inc
IQV
8
11
3
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Biontech SE
BNTX
4
13
5
0
0
22
Financial Forecasting
Based on analysts' estimates, ACAD EPS is projected to reach 0.194 in FY2026Q3, following reported EPS of 0.184 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
0.14
0.06
0.06
0.19
0.22
Actual
1.61
0.02
0.18
--
--
Surprise
+1074.36%
-65.62%
+219.35%
--
--
FAQs
What is ACADIA Pharmaceuticals Inc's expected revenue for the next quarter?
ACADIA Pharmaceuticals Inc's expected revenue is 331.52M.
What is ACADIA Pharmaceuticals Inc's price target?
Analysts forecast that ACADIA Pharmaceuticals Inc's price target is USD 32.06, with the highest forecast at USD 49.00 and the lowest forecast at USD 17.00.
How have ACADIA Pharmaceuticals IncACAD's recent earnings per share performed?
The market expectation was USD 0.18, while ACADIA Pharmaceuticals IncACAD's earnings per share (EPS) for the previous quarter was USD 0.02. EPS for the next quarter is expected at USD 0.19.
What is the analyst rating for ACADIA Pharmaceuticals Inc?
Based on the ratings of ACADIA Pharmaceuticals Inc's stock from 21 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.